🏅 FDA Orphan Designation

Zolinza

vorinostat

Manufacturer: Merck & Co., Inc.

Indicated for:

T-cell non-Hodgkin lymphomaOrphanPrimary cutaneous T-cell lymphoma

FDA-Approved Indications (2)

T-cell non-Hodgkin lymphomaOrphan Designation

Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.

Primary cutaneous T-cell lymphoma

ZOLINZA is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapi…

Population: patients with progressive, persistent or recurrent disease on or following two systemic therapies

Indications & Usage

1 INDICATIONS AND USAGE ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )

💙 Support Programs

View all →

ZOLINZA

Merck

Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.